Cantor Fitzgerald upgraded Madrigal Pharmaceuticals (MDGL) to Overweight from Neutral.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street
- Madrigal Pharmaceuticals reports Q3 EPS ($5.08) vs ($4.92) last year
- Madrigal Pharmaceuticals management to meet with Citizens
- Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms
- Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA